156 related articles for article (PubMed ID: 35093861)
1. Methionine Restriction: Ready for Prime Time in the Cancer Clinic?
Yamamoto J; Han Q; Simon M; Thomas D; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):641-644. PubMed ID: 35093861
[TBL] [Abstract][Full Text] [Related]
2. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
[TBL] [Abstract][Full Text] [Related]
3. Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
Han Q; Tan Y; Hoffman RM
Anticancer Res; 2020 May; 40(5):2813-2819. PubMed ID: 32366428
[TBL] [Abstract][Full Text] [Related]
4. Targeting Methionine Addiction of Cancer Cells with Methioninase.
Pokrovsky VS; Qoura LA; Demidova EA; Han Q; Hoffman RM
Biochemistry (Mosc); 2023 Jul; 88(7):944-952. PubMed ID: 37751865
[TBL] [Abstract][Full Text] [Related]
5. Methionine dependency and cancer treatment.
Cellarier E; Durando X; Vasson MP; Farges MC; Demiden A; Maurizis JC; Madelmont JC; Chollet P
Cancer Treat Rev; 2003 Dec; 29(6):489-99. PubMed ID: 14585259
[TBL] [Abstract][Full Text] [Related]
6. Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer.
Miyake M; Miyake K; Han Q; Igarashi K; Kawaguchi K; Barangi M; Kiyuna T; Sugisawa N; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Bouvet M; Endo I; Hoffman RM
Biochem Biophys Res Commun; 2023 Feb; 643():48-54. PubMed ID: 36586158
[TBL] [Abstract][Full Text] [Related]
7. Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey.
Hoffman RM
Expert Opin Biol Ther; 2015 Jan; 15(1):21-31. PubMed ID: 25439528
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
[TBL] [Abstract][Full Text] [Related]
9. Serum methionine depletion without side effects by methioninase in metastatic breast cancer patients.
Tan Y; Zavala J; Xu M; Zavala J; Hoffman RM
Anticancer Res; 1996; 16(6C):3937-42. PubMed ID: 9042316
[TBL] [Abstract][Full Text] [Related]
10. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
[TBL] [Abstract][Full Text] [Related]
11. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension.
Cavuoto P; Fenech MF
Cancer Treat Rev; 2012 Oct; 38(6):726-36. PubMed ID: 22342103
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Murakami T; Unno M; Hoffman RM
Cells; 2019 May; 8(5):. PubMed ID: 31052611
[TBL] [Abstract][Full Text] [Related]
13. [Methionine dependency of cancer cells: a new therapeutic approach?].
Durando X; Thivat E; Gimbergues P; Cellarier E; Abrial C; Dib M; Tacca O; Chollet P
Bull Cancer; 2008 Jan; 95(1):69-76. PubMed ID: 18230572
[TBL] [Abstract][Full Text] [Related]
14. Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
Han Q; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1921-1926. PubMed ID: 33813397
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term depletion of plasma methionine on the growth and survival of human brain tumor xenografts in athymic mice.
Kokkinakis DM; Schold SC; Hori H; Nobori T
Nutr Cancer; 1997; 29(3):195-204. PubMed ID: 9457739
[TBL] [Abstract][Full Text] [Related]
16. Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment.
Kubota Y; Han Q; Aoki Y; Masaki N; Obara K; Hamada K; Hozumi C; Wong ACW; Bouvet M; Tsunoda T; Hoffman RM
Cancer Diagn Progn; 2023; 3(3):272-281. PubMed ID: 37168964
[TBL] [Abstract][Full Text] [Related]
17. Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy.
Tan Y; Xu M; Tan X; Tan X; Wang X; Saikawa Y; Nagahama T; Sun X; Lenz M; Hoffman RM
Protein Expr Purif; 1997 Mar; 9(2):233-45. PubMed ID: 9056489
[TBL] [Abstract][Full Text] [Related]
18. Methods to Study the Role of Methionine-Restricted Diet and Methioninase in Cancer Growth Control.
Chaturvedi S; Bertino JR
Methods Mol Biol; 2019; 1866():1-12. PubMed ID: 30725403
[TBL] [Abstract][Full Text] [Related]
19. Extent and Instability of Trimethylation of Histone H3 Lysine Increases With Degree of Malignancy and Methionine Addiction.
Yamamoto J; Aoki Y; Inubushi S; Han Q; Hamada K; Tashiro Y; Miyake K; Matsuyama R; Bouvet M; Clarke SG; Endo I; Hoffman RM
Cancer Genomics Proteomics; 2022; 19(1):12-18. PubMed ID: 34949655
[TBL] [Abstract][Full Text] [Related]
20. Anticancer efficacy of methioninase in vivo.
Tan Y; Xu M; Guo H; Sun X; Kubota T; Hoffman RM
Anticancer Res; 1996; 16(6C):3931-6. PubMed ID: 9042315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
